Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. [electronic resource]
Producer: 20140521Description: 9247-53 p. digitalISSN:- 1083-351X
- Biocatalysis -- drug effects
- Cell Line, Tumor
- Cisplatin -- pharmacology
- Cross-Linking Reagents -- pharmacology
- Cyclin-Dependent Kinases -- deficiency
- DNA Repair -- genetics
- Drug Resistance, Neoplasm -- genetics
- Enzyme Inhibitors -- pharmacology
- Female
- Homologous Recombination -- drug effects
- Humans
- Mutation
- Ovarian Neoplasms -- enzymology
- Poly(ADP-ribose) Polymerase Inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.